Amber Woods completes PhD

December 12, 2017 by

In November, Amber Woods successfully defended her thesis “Effector CD8 T-cell entry into subcutaneous and intraperitoneal B16 melanoma tumors”. Her work in Vic Engelhard’s lab examined the requirements for CD8 T-cell entry into B16 melanomas growing in different anatomic locations. She found that VCAM-1 and CXCL9 were widely expressed on tumor-associated vasculature while E-selectin and MadCAM-1 were expressed only on SC or IP tumor vasculature, respectively. The presence of CD8 T-cells secreting IFNg, but not TNFa, was sufficient to drive VCAM-1 and CXCL9 expression on tumor endothelium. Interactions between a4b1/VCAM-1, CD44/HA, CXCR3/CXCL9 or 10, and LFA-1/ICAM-1 were required to mediate CD8 T cell entry into tumors. In a separate collaborative study, she found that treatment with the clinically-approved checkpoint blockade inhibitor, antiCTLA-4, enhanced CD8 T-cell representation and VCAM-1 expression on tumor-associated vasculature.

Congratulations Amber!